Watch ABOS. Know when insiders buy.
One email the day a filing lands. Free.
ABOS
Acumen Pharmaceuticals, Inc.
3.18
+0.09 +2.91%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
61
WATCH · shorts 61
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $230MP/E —DIV YIELD —FCF YIELD -39.91%REV TTM —NET INCOME −$105MNET CASH $47.5M52W 1.23 – 3.37SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$32.6M | −$32.7M | — | -0.45 | −$18.1M | $0 | −$18.1M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$21.1M | −$20.7M | — | -0.33 | −$24.1M | $0 | −$24.1M | May 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$25.2M | −$25.1M | — | -0.41 | −$19.1M | $0 | −$19.1M | Mar 26 |
| Q3 2025 · Sep 30 | — | — | — | −$26.5M | −$26.5M | — | -0.44 | −$30.5M | $0 | −$30.5M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$41.8M | −$41M | — | -0.68 | −$31.8M | $9K | −$31.8M | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$30.4M | −$28.8M | — | -0.48 | −$34.1M | $79K | −$34.2M | May 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$39.6M | −$37.2M | — | -0.62 | −$27.2M | $0 | −$27.2M | Mar 26 |
| Q3 2024 · Sep 30 | — | — | — | −$32.3M | −$29.8M | — | -0.50 | −$24.6M | $0 | −$24.6M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$24.4M | −$20.5M | — | -0.34 | −$16.5M | $5K | −$16.6M | Aug 12 |
| Q1 2024 · Mar 31 | — | — | — | −$17.8M | −$14.9M | — | -0.25 | −$17.9M | $11K | −$17.9M | May 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$18.5M | −$16.5M | — | -0.29 | −$8.3M | $14K | −$8.3M | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$16M | −$13M | — | -0.24 | −$12.9M | $7K | −$12.9M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$123.8M | −$121.3M | — | -2.00 | −$115.5M | $88K | −$115.6M | — | — |
| FY2024 · to Dec 31 | — | — | −$114M | −$102.3M | — | -1.71 | −$86.2M | $16K | −$86.2M | — | — |
| FY2023 · to Dec 31 | — | — | −$61.1M | −$52.4M | — | -1.08 | −$43.1M | $21K | −$43.1M | — | — |
| FY2022 · to Dec 31 | — | — | −$45.2M | −$42.9M | — | -1.06 | −$35.2M | $161K | −$35.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$19.6M | −$100.6M | — | -5.02 | −$18M | $40K | −$18M | — | — |
| FY2020 · to Dec 31 | — | — | −$7.9M | −$7.3M | — | -17.48 | −$7.5M | — | — | — | — |
Every number comes from Acumen Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.